|
USA-509905-Importers Κατάλογοι Εταιρεία
|
Εταιρικά Νέα :
- Hemophilia Therapies - Rare Disease Advisor
Xyntha ® (antihemophilic factor [recombinant]) is a recombinant factor VIII indicated for the on-demand treatment, perioperative management, and routine prophylaxis of bleeding in patients with hemophilia A It temporarily replaces FVIII in patients with hemophilia A to aid in hemostasis
- FDA Approves Novel Treatment for Hemophilia A or B, with or . . .
Today, the U S Food and Drug Administration approved a novel treatment for hemophilia A or B, with or without factor VIII or IX inhibitors (neutralizing antibodies)
- Discussing Factor VIII Infusions With Hemophilia Patients
By educating patients on their factor VIII activity and different treatment options, healthcare providers can set individualized and achievable goals This collaborative approach may enhance adherence to treatment, reduce bleeding episodes, and improve overall quality of life
- Acquired Hemophilia Treatment Management - Medscape
Recombinant antihemophilic factor, porcine sequence Historically, porcine factor VIII has provided a good effect A porcine sequence recombinant FVIII (rpFVIII; Obizur) was approved by the US Food and Drug Administration (FDA) in 2014 for treatment of bleeding episodes in adults with acquired hemophilia
- Antihemophilic factor (intravenous route) - Mayo Clinic
Antihemophilic factor (AHF) injection is used to treat, control, prevent, and decrease the frequency of bleeding episodes, and prevent bleeding during surgery in patients with hemophilia A (congenital Factor VIII deficiency) Antihemophilic factor (AHF) is a protein that is produced naturally in the body
|
|